MC ROUND TABLES - March 03, 2021
The annual American Society of Hematology (ASH) meeting is the most important scientific meeting of the year for the hematology community. It is held annu... Read More
MC ROUND TABLES - February 09, 2021
Sometimes we are compelled to learn about things that we never thought would be important in our lives. Ask any myeloma patient or caregiver. That&rsqu... Read More
MC ROUND TABLES - January 29, 2021
Side effects of various myeloma treatments—chemotherapy, bone-strengthening drugs, monoclonal antibodies, transplant—can be as bad or worse than the... Read More
MC ROUND TABLES - January 16, 2021
High-risk disease poses the most difficult questions in myeloma treatment. Increasing knowledge about genetics provides information about which targets to... Read More
MC ROUND TABLES - January 08, 2021
Fear, uncertainty, and pessimism accompany virtually every cancer diagnosis, especially if most patients, like those with myeloma, have never even heard the wor... Read More
MC ROUND TABLES - December 23, 2020
Chimeric antigen receptor T (CAR T) cell therapies are a promising category of many immunotherapies currently being integrated into myeloma treatment. ... Read More
MC ROUND TABLES - December 18, 2020
Autologous stem cell transplant (ASCT) is an essential part of many myeloma patients' treatment strategies. Among the first questions physicians ... Read More
MC ROUND TABLES - December 05, 2020
Bone pain is often the first symptom myeloma patients experience—often before they have been diagnosed—because bone degeneration is one of the most ... Read More
MC ROUND TABLES - November 03, 2020
Precursor conditions of myeloma may or may not progress to active myeloma, but they must be monitored regularly to determine if they are progressing. Mono... Read More
MC ROUND TABLES - October 11, 2020
Imaging techniques like X-rays and early generation MRI were once used to determine the extent of bone damage in myeloma patients—damage done by myeloma c... Read More
MC ROUND TABLES - October 03, 2020
“As our drugs got better, our need to measure got more important.” Dr. Jeffrey Wolf, UC San Francisco Minimal residual disease (MRD) is fa... Read More
MC ROUND TABLES - September 25, 2020
Research and approval of drug treatments for myeloma continues to move forward, despite the limitations imposed by the pandemic, increasing options, improving q... Read More
MC ROUND TABLES - September 22, 2020
Knowing about genetics is not just for scientists anymore. To be an informed myeloma patient it is essential to know what your specific genetic markers ar... Read More